{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:59:49Z","timestamp":1787979589063,"version":"build-2784847793"},"reference-count":38,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circulating tumor mast cells (CTMCs) have been identified in the blood of a small number of patients with advanced systemic mastocytosis (SM). However, data are limited about their frequency and prognostic impact in patients with MC activation syndrome (MCAS), cutaneous mastocytosis (CM) and nonadvanced SM. We investigated the presence of CTMCs and MC-committed CD34+ precursors in the blood of 214 patients with MCAS, CM, or SM using highly sensitive next-generation flow cytometry. CTMCs were detected at progressively lower counts in almost all patients with advanced SM (96%) and smoldering SM (SSM; 100%), nearly half of the patients (45%) with indolent SM (ISM), and a few patients (7%) with bone marrow (BM) mastocytosis but were systematically absent in patients with CM and MCAS (P &amp;lt; .0001). In contrast to CTMC counts, the number of MC-committed CD34+ precursors progressively decreased from MCAS, CM, and BM mastocytosis to ISM, SSM, and advanced SM (P &amp;lt; .0001). Clinically, the presence (and number) of CTMCs in blood of patients with SM in general and nonadvanced SM (ISM and BM mastocytosis) in particular was associated with more adverse features of the disease, poorer-risk prognostic subgroups as defined by the International Prognostic Scoring System for advanced SM (P &amp;lt; .0001) and the Global Prognostic Score for mastocytosis (P &amp;lt; .0001), and a significantly shortened progression-free survival (P &amp;lt; .0001) and overall survival (P = .01). On the basis of our results, CTMCs emerge as a novel candidate biomarker of disseminated disease in SM that is strongly associated with advanced SM and poorer prognosis in patients with ISM.<\/jats:p>","DOI":"10.1182\/blood.2021012694","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T20:58:40Z","timestamp":1631134720000},"page":"572-583","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5096-791X","authenticated-orcid":false,"given":"Ana","family":"Henriques","sequence":"first","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain;"},{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-5663","authenticated-orcid":false,"given":"Javier I.","family":"Mu\u00f1oz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-7255","authenticated-orcid":false,"given":"Laura","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain;"},{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9547-4844","authenticated-orcid":false,"given":"Almudena","family":"Matito","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain;"},{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-5432","authenticated-orcid":false,"given":"Lidia","family":"Torres-Rivera","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-7512","authenticated-orcid":false,"given":"Mar\u00eda","family":"Jara-Acevedo","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"},{"name":"Sequencing Service, NUCLEUS, University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-6211","authenticated-orcid":false,"given":"Carolina","family":"Caldas","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-7398","authenticated-orcid":false,"given":"Andrea","family":"Mayado","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-1391","authenticated-orcid":false,"given":"Alba","family":"P\u00e9rez-Pons","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1386","authenticated-orcid":false,"given":"Andr\u00e9s C.","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-4473","authenticated-orcid":false,"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[{"name":"Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain;"},{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-7230","authenticated-orcid":false,"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"Spanish Network on Mastocytosis, Toledo and Salamanca, Spain;"},{"name":"Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, University of Salamanca, Salamanca, Spain;"},{"name":"Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022012716231717300_B1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"issue":"4","key":"2022012716231717300_B2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"4","key":"2022012716231717300_B3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"4","key":"2022012716231717300_B4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol."},{"issue":"4","key":"2022012716231717300_B5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood."},{"issue":"11","key":"2022012716231717300_B6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022012716231717300_B7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol."},{"issue":"3","key":"2022012716231717300_B8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol."},{"issue":"7","key":"2022012716231717300_B9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/jcm10071420","article-title":"Bone marrow mastocytosis: a diagnostic challenge","volume":"10","author":"Zanotti","year":"2021","journal-title":"J Clin Med."},{"issue":"1","key":"2022012716231717300_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2014.01.018","article-title":"Mast cell progenitors: origin, development and migration to tissues","volume":"63","author":"Dahlin","year":"2015","journal-title":"Mol Immunol."},{"issue":"4","key":"2022012716231717300_B11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2015-06-650648","article-title":"Lin- CD34hi CD117int\/hi Fc\u03b5RI+ cells in human blood constitute a rare population of mast cell progenitors","volume":"127","author":"Dahlin","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022012716231717300_B12","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/all.13413","article-title":"Characterization of CD34+ hematopoietic cells in systemic mastocytosis: potential role in disease dissemination","volume":"73","author":"Mayado","year":"2018","journal-title":"Allergy."},{"issue":"16","key":"2022012716231717300_B13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood-2017-03-773374","article-title":"KIT signaling is dispensable for human mast cell progenitor development","volume":"130","author":"Dahlin","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2022012716231717300_B14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ajh.21713","article-title":"Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge","volume":"85","author":"Arredondo","year":"2010","journal-title":"Am J Hematol."},{"issue":"19","key":"2022012716231717300_B15","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2011-02-335950","article-title":"Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor","volume":"118","author":"Georgin-Lavialle","year":"2011","journal-title":"Blood."},{"issue":"9","key":"2022012716231717300_B16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2016.105","article-title":"Detection of circulating mast cells in advanced systemic mastocytosis","volume":"30","author":"Dahlin","year":"2016","journal-title":"Leukemia."},{"issue":"1","key":"2022012716231717300_B17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br J Haematol."},{"issue":"21","key":"2022012716231717300_B18","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"2022012716231717300_B19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"2022012716231717300_B20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia."},{"issue":"12","key":"2022012716231717300_B21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J."},{"issue":"9","key":"2022012716231717300_B22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia."},{"issue":"3","key":"2022012716231717300_B23","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(20)30400-2","article-title":"Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study","volume":"8","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2021","journal-title":"Lancet Haematol."},{"issue":"12","key":"2022012716231717300_B24","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol."},{"issue":"10","key":"2022012716231717300_B25","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia."},{"issue":"1","key":"2022012716231717300_B26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.5RU0614-296R","article-title":"The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis","volume":"97","author":"Teodosio","year":"2015","journal-title":"J Leukoc Biol."},{"issue":"2","key":"2022012716231717300_B27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn."},{"issue":"8","key":"2022012716231717300_B28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod Pathol."},{"issue":"1","key":"2022012716231717300_B29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia."},{"issue":"5","key":"2022012716231717300_B30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2019","journal-title":"Blood."},{"key":"2022012716231717300_B31","doi-asserted-by":"crossref","first-page":"112684","DOI":"10.1016\/j.jim.2019.112684","article-title":"Immunophenotypic dissection of normal hematopoiesis","volume":"475","author":"Orfao","year":"2019","journal-title":"J Immunol Methods."},{"issue":"7","key":"2022012716231717300_B32","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood."},{"issue":"17","key":"2022012716231717300_B33","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/bloodadvances.2018019539","article-title":"Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells","volume":"2","author":"Grootens","year":"2018","journal-title":"Blood Adv."},{"issue":"4","key":"2022012716231717300_B34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.2830340409","article-title":"Malignant mastocytosis with circulating mast cells","volume":"34","author":"Torrey","year":"1990","journal-title":"Am J Hematol."},{"issue":"12","key":"2022012716231717300_B35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc."},{"issue":"7","key":"2022012716231717300_B36","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood."},{"issue":"1","key":"2022012716231717300_B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom."},{"issue":"7","key":"2022012716231717300_B38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/4\/572\/1864216\/bloodbld2021012694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/4\/572\/1864216\/bloodbld2021012694.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T14:51:58Z","timestamp":1699455118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/4\/572\/476816\/Frequency-and-prognostic-impact-of-blood"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021012694","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}